Effects of melatonin supplementation on diabetes: A systematic review and meta-analysis of randomized clinical trials.
Study Goal
The researchers aimed to evaluate the effects of melatonin supplementation on diabetes parameters (fasting blood glucose, insulin resistance, glycated hemoglobin) compared to placebo in humans.
Results Summary
The meta-analysis found significant benefits of melatonin supplementation in reducing fasting blood glucose, with 56% of included studies showing positive effects on diabetes parameters compared to placebo. However, no significant results were observed for insulin resistance and glycated hemoglobin.
Population
Humans with diabetes (specific population details not provided in the abstract).
Effective Dosage
Not specified in the abstract.
Duration
Not specified in the abstract.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
melatonin supplementation | neutral | diabetes | - | - | appears as a supplement capable of helping with | #1 |
melatonin supplementation | no change | insulin resistance and glycated hemoglobin | - | no significant change | showed no significant results in | #2 |
melatonin supplementation | decrease | diabetes parameters | - | - | showed benefits in | #3 |
melatonin supplementation | decrease | fasting blood glucose | - | -4.65; 95% CI: -8.06, -1.23; p = < 0.01 | showed significant results for | #4 |
melatonin supplementation | decrease | diabetes parameters | - | - | was useful for reducing | #5 |
BACKGROUND & AIMS: Melatonin appears as a supplement capable of helping with diabetes. However, there is no evidence from meta-analyses that showed significant results in insulin resistance and glycated hemoglobin. This study aimed to review the literature on randomized clinical trials that evaluated melatonin supplementation effects, compared to placebo, on diabetes parameters in humans. METHODS: We conducted a systematic review and meta-analysis in the following databases: Pubmed, LILACS, Scielo, Scopus, Web of Science, Cochrane, and Embase. We included randomized clinical trials investigating melatonin supplementation's effects, compared to placebo, on fasting blood glucose, insulin resistance, and glycated hemoglobin. Non-randomized clinical trials, observation studies, and animal models were excluded. The Cochrane scale assessed the quality of the studies. We conducted a meta-analysis on fasting blood glucose, insulin resistance, and glycated hemoglobin. RESULTS: Sixteen studies were included, of which 56% showed benefits from supplementation with melatonin in diabetes parameters compared with placebo. Our meta-analysis showed significant results for fasting blood glucose [mean difference: -4.65; 95% CI: -8.06, -1.23; p = < 0.01; I CONCLUSIONS: Our results showed that melatonin supplementation was useful for reducing diabetes parameters when compared to placebo.